Global Breast Cancer Antibodies Biomarkers & Clinical Trials Insight 2028 Report `Highlights:
- Global Breast Cancer Antibodies Market Opportunity: > USD 15 Billion
- Breast Cancer Antibodies Clinical Trials Insight: > 150 Drugs In Trials
- Breast Cancer Biomarkers Sourced During Clinical Trials
- Breast Cancer Biomarkers Insight By Antibodies Classification
- Insight On Biomarkers Sourced From Trials By Drugs & Indication
- Biomarker Name & Function Insight By Antibody
- Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication
Download Report: https://www.kuickresearch.com/ccformF.php?t=1646994975
Global Immune Checkpoint Inhibitors Biomarkers & Clinical Trials Insight 2028 Report Highlights:
- Global Immune Checkpoint Inhibitors Market Opportunity: > USD 30 Billion
- Immune Checkpoint Inhibitors Clinical Trials Insight: CTLA-4, LAG3, PD-1/PD-L1, TIGIT Inhibitors
- Immune Checkpoint Inhibitors Clinical Trials Insight: > 300 Drugs In Trials
- Biomarkers sourced During clinical Trials
- Biomarkers Insight By Immune Checkpoint Inhibitors Classification
- Insight On Biomarkers Sourced From Trials By Drugs & Indication
- Biomarker Name & Function Insight By Immune Checkpoint Inhibitor Drug
- Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication
Download Report: https://www.kuickresearch.com/report-immune-checkpoint-inhibitors-biomarkers
Antibodies have been utilized as therapeutics since 19th century in the form of patient or animal derived sera to treat infectious diseases. However, the advancement in the field of recombinant DNA technology has led to development of several methods to produce novel therapeutic antibody constructs including monoclonal antibodies, bispecific antibodies, antibody drug conjugates, trispecific antibodies, and several others. Among all approaches, monoclonal antibody based immunotherapy is considered as main component of cancer therapy, alongside surgery, radiation, and chemotherapy.
Several monoclonal antibodies targeting different receptors on the cancer cells have entered the market such as Rituximab targets CD20, Herceptin targets HER2 receptors, Bevacizumab targets VEGF growth factor, and several others. Researchers have identified several mechanisms which are thought to play important role in the anti-tumor activity of monoclonal antibody. These include signaling mediated by cross-linking of surface antigen that leads to cell death, blocking an activation signal that is necessary for continued cell growth, antibody-dependent cellular cytotoxicity (ADCC), complement mediated cytotoxicity (CMC) and the ability of monoclonal antibody to alter the cytokine or enhance development of an active anti-tumor immune response. Owing to their novel mechanism of action and large number of drugs approved, this segment is expected to dominate the market during the forecast period.
In addition to this, monoclonal antibodies targeting immune checkpoints have also entered the market which block different proteins such as CTLA-4 (cytotoxic T lymphocyte-associated protein 4), PD-1 (programmed cell death protein 1), and PD-L1 (programmed death-ligand 1). To date, sixteen immune checkpoint inhibitors including Keytruda, Bavencio, Opdivo, Yervoy, Jemperli Tecentriq, Imfinzi, and Libtayo has entered the global market which has shown high adoption rates among cancer patients. Further advancement in the field of immune checkpoint therapy and considerable research activities has also led to identification of a few other immune checkpoints which also have potential for anticancer immunotherapy such as lymphocyte activation gene-3 (LAG-3), T-cell membrane protein-3, signal transducer and activator of transcription 3 (STAT3), T cell immunoglobulin and ITIM domain (TIGIT), and others which are mainly confined to clinical trials.
Apart from monoclonal antibodies, two bispecific antibodies have also entered the market including Blincyto and Rybervant. Bispecific antibodies due to the combination of two binding specificities, improve the selectivity and efficacy of antibody-based treatment of human disease. They are designed to combine specificities of two antibodies and simultaneously involved in addressing different antigens or epitopes. Bispecific antibodies can place targets into close proximity, either to support protein complex formation on one cell, or to trigger contacts between cells. These molecules then cause the lysis of the target by T-cell mediated cytotoxicity, Phagocytosis, ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) or ADCP (Antibody-Dependent Cell-Mediated Phagocytosis).
Further to enhance the efficacy of chemotherapy drugs and to reduce the systemic toxicities associated with them, researchers have developed antibody drug conjugates. Unlike conventional cancer therapies which damage the healthy tissues, novel antibody drug conjugates utilize monoclonal antibodies to specifically bind to tumor associated targeted antigens and deliver a highly cytotoxic drug. Upon intravenous administration, antibody drug conjugates bind to their target antigens and are internalized through receptor mediated endocytosis. This facilitates the subsequent release of the cytotoxin, which eventually leads to apoptotic cell death of the cancer cell. To date, several antibody drug conjugates including Kadcyla, Enhertu, Lumoxiti, Tivdak, Polivy, and others have entered the market which have shown high efficacy in the management of several cancers.
Contact:
Neeraj Chawla
Kuick research
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com